Targeting NAD + Synthesis to Potentiate CD38-Based Immunotherapy of Multiple Myeloma

Targeting NAD + Synthesis to Potentiate CD38-Based Immunotherapy of Multiple Myeloma

Antibodies targeting CD38, a NAD -degrading enzyme, have emerged as a promising immunotherapy against multiple myeloma (MM). Currently, the mechanisms by which anti-CD38 antibodies establish their therapeutic effects are poorly understood. Here, we advocate for the depletion of NAD to enhance the ef...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Trends in Cancer 2020-01, Vol.6 (1), p.9-12
Hauptverfasser: Kennedy, Barry E, Sadek, Maryanne, Elnenaei, Manal O, Reiman, Anthony, Gujar, Shashi A
Format: Artikel
Sprache:eng
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Antibodies targeting CD38, a NAD -degrading enzyme, have emerged as a promising immunotherapy against multiple myeloma (MM). Currently, the mechanisms by which anti-CD38 antibodies establish their therapeutic effects are poorly understood. Here, we advocate for the depletion of NAD to enhance the efficacy of anti-CD38-based immunotherapies in MM.
ISSN:2405-8033
2405-8025
DOI:10.1016/j.trecan.2019.11.005